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1. Introduction
The occurrence of graft rejection and/or graft-versus-host disease (GVHD) after allogeneic
hematopoietic stem cell transplantation (allo-HSCT) is largely depended on whether the re‐
cipient and the donor have matched HLA types. Under normal circumstances, the individu‐
al with completely matched HLA antigens can be the donor. However, due to the high level
of HLA polymorphism, the major obstacle in the allogeneic hematopoietic stem cell trans‐
plantation is to find a donor with HLA antigens that are a perfect match. This can prove to
be quite problematic.
In 1954, an organ transplantation team led by Dr. Merri at Harvard University successfully
completed a kidney transplantation between identical twins for the first time. From then on, the
importance of histocompatibility in organ transplantation has been well recognized. The first
human bone marrow transplantation between identical twins in 1957 provided a new ap‐
proach for the treatment of leukemia and other hematologic malignancies. As a result, the basic
research on HLA as well as the HLA typing techniques gained much attention over the next 20
years. The short-term survival rate of organ transplantation has been greatly improved since
the 1980s due to the clinical application of immunosuppressive agents such as CsA. These suc‐
cesses,as well as the defects and limitations in serotyping and cellular typing of HLA, the clini‐
cal value of HLA typing has been largely ignored in the medical community.
With the advance of research in immunology and transplantation immunology, particularly
in the structure and function of HLA in the 1990s, new technology for HLA typing has
emerged and continues to improve. Terasaki and Opelz analyzed a large amount of organ
transplantation cases performed in major transplantation centers around the world. The
role, status and importance of HLA typing in hematopoietic stem cell transplantation have
been recognized once again. Overall, HLA typing is required in hematopoietic stem cell
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transplantation. HLA compatibility not only significantly reduces the incidence of acute re‐
jection, but also significantly reduces the incidence of chronic rejection. HLA compatibility is
one of the most critical factors that affect the long-term survival of the graft.
HLA loci are the most genetically variable gene loci in human. Two hundred and twenty
four loci of HLA complex have been identified so far. Among these, 128 are functional loci
that encode proteins, and 39.8% of HLA genes are related to the immune system, particular‐
ly those belong to class II loci. Almost all these genes display immune-related functions. Ap‐
proximately 100 HLA genes loci have been cloned and named, and at least 18 of them have
alleles. Since these loci have various amounts of alleles and each allele encodes a corre‐
sponding HLA antigen, the HLA complex has the most abundant genetic polymorphism in
the human immune system.
Figure 1. Increasing number of HLA alleles from 1987 to July 2012
Systemic investigations of the alleles in HLA loci began in 1987. There were just over 10
identified alleles at that time. The allele numbers in HLA-I and HLA-II loci were increased
to 100 and 50 respectively in 1989. The allele number of HLA-I and HLA-II reached 1028 in
2000. As of July 2012, the total allele number of HLA loci has reached 8016. HLA-A, HLA-B
and HLA-C loci have 2013, 2605 and 1551 alleles respectively. DRA site has 34 and DRB site
has 1260 alleles. DQA1 and DQB1 sites have 47 and 176 alleles respectively, and DPA1 and
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DPB1 sites have 34 and 155 alleles, respectively (Fig 1). Theoretically, it is very difficult to
find an unrelated donor with a perfectly matched HLA genotype (at the allele level) in the
general population.
The polymorphism of HLA makes it difficult to find a match between unrelated donor and
recipient in the allotransplantation. Currently, the most commonly used HLA typing in or‐
gan transplantations around the world is based on HLA-A, B, C and DR genes. There are up
to 7400 alleles in these genes corresponding to more than 100 specific antigens. With the in‐
creasing number of patients who need hematopoietic stem cell transplantation, the lack of
appropriate donors has become a significant challenge. Therefore, there is an urgent need to
develop novel scientific, practical, and feasible HLA typing methods in the field of hemato‐
poietic stem cell transplantation.
2. Principles for HLA typing strategy in allogeneic hematopoietic stem
cell transplantation
The first successful human bone marrow transplantation between identical twins in 1957
has provided a new approach for the treatment of leukemia and other hematologic malig‐
nancies.  After  the  successful  hematopoietic  stem  cell  transplantation  between  unrelated
donor and recipient with matched HLA, a bone marrow donor registry was established in
1988 (National Marrow Donor Program, NMDP) in the USA. Later on, a public cord blood
bank was established. According to the World Marrow Donor Association (WMDA), as of
July 2012, the association has 68 bone marrow banks in 49 countries and regions. It also
has 46 cord blood banks in 30 countries and regions. The registered bone marrow and um‐
bilical  cord blood donors have exceeded 20 million.  Meanwhile,  the technology of  HLA
typing  has  been  transformed from simple  serotyping  to  more  accurate  genotyping.  Al‐
though there are hundreds of reports regarding the effect of HLA matching degree on the
efficacy of hematopoietic stem cell transplantation, these results are not consistent due to
the differences in sample size, disease type and stage, and HLA typing. In addition, the in‐
terpretation of  HLA genotyping results  and their  biological  significance is  becoming in‐
creasingly  complicated.  It  is  challenging  for  the  clinicians  outside  of  the  HLA  field  to
select  an unrelated donor with the best-matched HLA. To meet  this  challenge,  WMDA,
NMDP  of  the  USA  and  European  Federation  of  Immunogenetics  (EFI)  have  provided
guidelines for HLA typing.
2.1. Correlation between HLA allele and HLA antigen specificity
There is a fundamental difference in the result and biological significance between HLA
serotyping and genotyping. In the HLA serotyping, HLA antibodies are used to identify
the HLA antigens on the surface of lymphocytes. HLA antigens are proteins that can be
recognized by the host immune system during blood transfusion, organ transplantation, as
well as pregnancy. Specific antibodies against HLA antigens are the basis of the identifica‐
tion  of  the  HLA antigens.  The  HLA antisera  used in  serotyping,  regardless  of  whether
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they are from the same species or different species, are all produced by immune stimula‐
tion with HLA antigens or peptides. In the HLA genotyping analysis, a specific HLA gene
fragment is amplified in vitro from an individual’s genomic DNA using synthetic oligonu‐
cleotide probes or primers. The genetic difference caused by variant HLA gene alleles is
reflected by the variation in the DNA sequence. Therefore, HLA genotyping can identify
all HLA alleles at the DNA level while HLA serotyping can only detect part of variants.
The  efficacy  of  bone  marrow transplantation  is  closely  related  to  the  matching  level  of
HLA between the donor and recipient. However, the HLA genotyping result does not di‐
rectly reflect the antigen that causes immune rejection after the transplantation. Therefore,
for the purpose of clinical relevance, the result of HLA genotyping should be converted to
the HLA specificity. To this end, the NMPD and the University of California in Los An‐
gels (UCLA) established the International Cell Exchange program, through which correla‐
tions between the HLA alleles and HLA antigen specificities are established by comparing
a large amount of testing results worldwide. The dictionary of HLA alleles and their corre‐
sponding antigen specificities is under constant updating. As of 2008, 70% of HLA alleles
have been correlated to HLA antigen specificities. The rest 30% alleles are rare alleles with
a frequency less than 1 in 10,000.  Therefore,  their  clinical  values are relatively low. The
HLA genotyping result  can be easily converted to the HLA antigen specificity by using
this HLA dictionary.
2.2. The number of donor with matched HLA gene types is much lower than that with
matched HLA antigens
The criteria of matched HLA between the donor and recipient are different for the HLA
genotyping and HLA serotyping in the bone marrow transplantation. From the HLA dic‐
tionary,  one can tell  that  the HLA antigen specificity is  unique,  while  a  unique antigen
may have one or more corresponding HLA alleles. For example, HLA-DR10 antigen only
corresponds to HLA-DRB1*1001 allele, while HLA-DR11 antigen corresponds to 21 alleles
such as HLA-DRB1*1101, 1102 and 1103. Therefore, the choice of donor for bone marrow
transplantation may differ, depending on the method of HLA typing. For example, a do‐
nor and recipient listed in Table 1 may have matched HLA according to antigen specifici‐
ty.  However,  their  HLA genotypes may not  match.  Which method is  more accurate for
bone marrow transplantation is currently under investigation. Statistical analysis indicates
that the chance of finding matched HLA genotypes in a random population is much low‐
er than finding matched HLA antigens. For instance, as of February 2002, HLA-A, B and
DR  have  93  specific  antigens.  HLA-A,  B  and  DR  have  25,  50  and  18  loci  respectively,
which can generate 2.2 x 10 4 haplotypes. The genotype number of these haplotypes can be
up  to  2.5x1013.  Currently,  there  are  2100  alleles  have  been  identified  in  HLA-A,  B  and
DRB1 genes. Their combination will yield 3.4 x10 7 haplotypes. As a result, the number of
HLA-A, B and DRB1 genotypes in a population can be up to 5.78x1015,  making it almost
impossible to find the matched HLA genotype in a random population. In other words,
the HLA genotypes of the donor and the recipient are always more or less mismatched in
bone marrow transplantation. Because of this, the concept of permissible HLA mismatch‐
es has been introduced.
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matching status Recipient’s HLA type Donor’s HLA type
antigen gene Antigen gene Antigen gene
matched matched A2 A11 A* 0202 A*1101 A2 A11 A*0202 A*1101
B60 B62 B*4001 B*1501 B60 B62 B*4001 B*1501
DR4 DR8 DRB1*0402 DRB1*0801 DR4 DR8 DRB1*0402 DRB1*0801
matched unmatched A2 A11 A* 0202 A*1101 A2 A11 A*0205 A*1102
B60 B62 B*4001 B*1501 B60 B62 B*4007 B*1504
DR4 DR8 DRB1*0402 DRB1*0801 DR4 DR8 DRB1*0404 DRB1*0803
unmatched unmatched A2 A11 A* 0202 A*1101 A2 A30 A*0201 A*3001
B60 B62 B*4001 B*1501 B61 B62 B*4002 B*1501
DR4 DR8 DRB1*0402 DRB1*0801 DR4 DR11 DRB1*0401 DRB1*1102
Table 1. Examples of HLA antigen matching and allele matching between the recipient and the donor in bone
marrow transplantation
2.3. Permissible HLA mismatches
In the case of permissible HLA mismatches, the donor and the recipient have mismatched
HLA in a bone marrow transplant. However, the mismatch does not cause a significantly
increased rate of GVHD or graft failure, and is acceptable for bone marrow transplantation.
Results from retrospective analyses suggest that mismatched alleles in HLA class I antigens
as well as alleles in HLA-DQ and DP loci have minimal impact on the efficacy of bone mar‐
row transplantation.
2.3.1. HLA class I antigen or allele mismatch
Petersdorf et al had investigated the effect of matching level of HLA class I antigens and alleles
on the success rate of bone marrow transplantation in 471 patients. The transplant failure rate is
0.7% in 280 cases with matched HLA-A, B and C genes, and is 0% in 47 cases with one of mis‐
matched heterozygous HLA-A, B or C gene. However, the failure rate in 51 cases with one of
mismatched HLA-A, B or C antigens is 14%, which is significantly higher than that in the con‐
trol group. In 76 cases with 2 or more mismatched antigens or genes, the transplant failure rate
is 17%. These results indicate that a single mismatched allele in the HLA class I gene does not in‐
crease the transplant failure rate, while a single mismatched antigen, or 2 or more mismatched
antigens or genes can significantly increase the transplant failure rate. These results support Pe‐
tersdorf’s hypothesis that the immune response caused by mismatched HLA class I alleles is
lower than that caused by mismatched antigens. Therefore, mismatched HLA class I genes are
permissible in the bone marrow transplantation, as long as HLA antigens match. Rubinstein et
al also believes that transplantation can be considered if there is only one mismatched allele.
For example, the recipient’s genotype is HLA-A*0202 while the donor’s genotype is HLA-
A*0203. This kind of mismatch does not increase the rate of immune rejection. Further analysis
indicates that whether a single allele mismatch is allowed in the transplantation also depends
on the type of corresponding mismatched amino acid and the position of that amino acid in the
HLA class I antigen. HLA class I molecules consist of a covalently bound heavy chain molecule
and a ฀2 microglobulin. The extracellular fragment of the heavy chain has 3 activity domains
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(฀1, ฀2 and ฀3), and the ฀1 and ฀2 domains form the peptide-binding region. The complex
of HLA and its bound peptide on the cell surface constitutes the ligand for the T-cell receptor
(TCR), thereby inducing an immune response. If there is only one mismatched allele between
the donor and recipient, the number of mismatched amino acids will be much lower, and may
rarely involve the amino acids for TCR binding. On the other hand, if the donor and the recipi‐
ent have a mismatched antigen, it may have many mismatched amino acids, and some of these
amino acids may be involved in peptide binding and TCR binding. This may explain why the
matching of HLA class I antigen is more important than the matching of genotype (Fig 2).
 
Figure 2. Spatial structure as well as the position and number of mismatched amino acid in the class I HLA with mis‐
matched donor-recipient genotypes (A) or mismatched donor-recipient antigens (B). The position of amino acid resi‐
due is labeled according to its position in the whole protein. Amino acid residues with dark blue color are located in
the ฀-sheet and involved in peptide binding. Amino acid residues located on the ฀ helix are colored with light blue.
Amino acid residues involved in TCR binding are in red. White amino acids are involved in neither TCR binding nor
peptide binding, while gray amino acids are involved in both TCR and peptide binding. Number of mismatched amino
acid involved in peptide binding and TCR binding in the class I HLA with mismatched donor-recipient genotypes (C)
and mismatched antigens (D). In panel D, patients with a transplant failure are in dark gray block.
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Further analysis by Petersdorf et al shows that one mismatched HLA-A, B or C antigen caus‐
es 71% transplant failure in 7 HLA homozygous patients, but causes 7% failure rate in 98
heterozygous patients, suggesting that for HLA homozygous patients, when a matched do‐
nor is not available, the homozygous donor with other matched heterozygous alleles should
be chosen. For example, the recipient’s HLA type is HLA-A2, B44 and DR8/9. Donor 1’s
HLA type is HLA-A2, B51, B46 and DR8/9. Donor 2’s HLA type is HLA-A2/11, B44, B46 and
DR8/9. In this case, donor 1 is preferred.
2.3.2. HLA class II antigen or allele mismatch
HLA class II genes encode antigens such as HLA-DR, DQ and DP. In order to understand
the importance of HLA class II genes in unrelated bone marrow transplantation, McGlave et
al have investigated the effect of mismatched DR, DQ and DP alleles on the result of trans‐
plantation. Data from NMDP that contain 831 chronic myeloid leukemia (CML) patients re‐
ceived bone marrow transplantation between 1988 and 1997 were analyzed. 696 patients
have matched HLA-A and B base on serotyping results. Among them, 565 (81%) have
matched DRB1 genotypes. Data analysis shows that matched HLA-DRB1 alleles can signifi‐
cantly improve graft survival and patient survival. While, mismatched HLA-DQA1, DQB1,
DPA1 and DPB1 genes do not significantly affect the GVHD incidence or transplantation re‐
sult. This result suggests that matching HLA-DRB1 alleles is an important factor in bone
marrow transplantation (Fig 3).
 
Figure 3. Effect of DRB1 matching level on patient’s survival rate (A) CML patient, (B) Patients with matched HLA-A, B
serotypes
2.4. HLA typing standard for hematopoietic stem cell transplantation
According to the guideline of World Bone Marrow Donor Association (WBDA) and Europe‐
an Federation for Immunogenetics (EFI), HLA typing of the donor in a large-scale bone mar‐
row center is generally limited to 2 digits after the asterisk in the WHO HLA nomenclature,
corresponding to the subtype of a specific HLA antigen. However, high-resolution HLA
typing should be performed for recipients and donors with matched HLA. In addition, the
typing of HLA class I genes should also include the locus C. Due to the increasingly recog‐
nized role of locus C in the immune rejection, the typing of HLA-C should be performed.
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When choosing a donor, the HLA-DRB1 gene of the donor and the recipient should have 4
identical digits after the asterisk in the WHO HLA nomenclature.
Although most commonly used methods for HLA genotyping cannot cover all genes, it does
not limit their applications in HLA typing for bone marrow transplantation. Among thousands
of identified HLA alleles, most of them are rare alleles. Therefore, it is not necessary to type all
HLA alleles. For instance, 244 expressing genes have been identified in DRB1 loci. Among
them, 148 (60%) alleles have corresponding specific DR antigens, while 96 alleles (40%) do not.
According to the NMDP, result of HLA-DRB1 typing in 65,752 donors shows that 86 alleles
have 0 frequency and the frequency of another 105 alleles is lower than 0.0002. In addition, the
total frequency of 10 alleles without corresponding antigens is 0.000084. Therefore, identifica‐
tion of the rest 43 DRB1 alleles will cover 99.6% of HLA-DR antigen specificities, which is suffi‐
cient for the screen of donor in hematopoietic stem cell transplantation.
3. PCR based HLA genotyping methods
The technology for HLA typing has evolved from the serological level to the cellular level, to
the molecular level. Serotyping was the mainstream method for HLA type and has played a
critical role in organ transplantations before 1990s. However, most HLA antisera are polyclo‐
nal and often have cross-reactions, making it difficult to distinguish antigens with subtle struc‐
tural differences, and leading to misidentifications. Further more, many factors, such as a
prolonged transportation time of the blood sample and excessive amount of immature cells,
may affect the result of serotyping and cellular typing. These are the limitations of traditional
HLA typing methods. The development of polymerase chain reaction (PCR) and its applica‐
tion in biomedical sciences has made the HLA typing at the DNA level possible. Therefore, us‐
ing molecular methods to type HLA at the DNA level has gradually replaced serotyping and
cellular typing. Commonly used DNA based HLA typing methods include PCR based se‐
quence specific primers (PCR-SSP), and PCR based restriction fragment length polymorphism
(PCR-RFLP), single-strand conformation polymorphism (PCR-SSCP), sequence-specific oligo‐
nucleotide (PCR-SSO) and single nucleotide polymorphism (PCR-SNP).
3.1. PCR-SSP (sequence specific primers)
To identify point mutations in a DNA molecule, Newton invented the amplification refrac‐
tory mutation system (ARMS) for in vitro DNA amplification. The technique requires an al‐
lele sequence specific 3’ primer for the PCR amplification. Otherwise the PCR reaction will
not be effective. This is because the Taq DNA polymerase used in the PCR reaction has 5’ to
3’ polymerase activity and 5’ to 3’ exonuclease activity but lacking 3’ to 5’ exonuclease activ‐
ity. Therefore, the enzyme cannot repair the single mismatched nucleotide in the 3’ primer.
In order to amplify the allele with a specific sequence, the primer with the corresponding
sequence is designed. The conditions for PCR reaction are strictly controlled so that the am‐
plification of the fragment with its sequence perfectly matching the primer is much more ef‐
fective than the sequence with one or more mismatched nucleotide. One mismatched
nucleotide between the 3’ primer and the template is sufficient to prevent the amplification.
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The PCR product is further analyzed by electrophoresis to determine whether the amplicon
corresponds to the anticipated primer-specific product. Since the DNA sequence of HLA
class I and class II genes are known, PCR primers can be designed based on the specific se‐
quence of each allele for PCR-SSP genotyping.
The encoding allele sequences of various HLA antigens can be amplified with sequence
specific primers. By controlling the conditions of PCR, a specific primer can only amplify
its corresponding allele,  and not other alleles.  Therefore,  the presence of a PCR product
can be used to determine the presence or  absence of  a  specific  allele.  The specificity  of
PCR product can be further determined by agarose gel  electrophoresis.  Fig 4 shows the
principle of PCR-SSP.
Figure 4. The diagram of PCR reaction
In the first step of PCR reaction, double-stranded DNA is denatured into single-stranded
DNA. In the second step, specific primers anneal to the template DNA. In the third step,
double stranded DNA is generated by TaqDNA polymerase by incorporating 4 types of
dNTP into the newly synthesized DNA strand. After 30-40 cycles of amplification, the target
gene is increased to 108 fold.
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The main advantage of this method is that it is simple and fast, and the result is easy to in‐
terpret. The heterozygosity can be easily detected as well. Therefore, PCR-SSP is the current‐
ly most used method for HLA typing. There are several FDA approved high-resolution and
low-resolution detection kits available for HLA class I and class II typing. Many clinical lab‐
oratories in China have been using this method for accurate pre-transplantation HLA typ‐
ing. The procedure of PCR-SSP is shown in Fig 5. One disadvantage of this method is that it
requires multiple primers in order to amply all relevant alleles.
Figure 5. The experimental procedure of PCR-SSP
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3.2. PCR-RFLP (restriction fragment length polymorphism)
Restriction endonucleases have unique recognition sites. Using computer analysis, restriction
endonucleases that can recognize HLA sequence polymorphism are chosen to digest the PCR
product. Because of sequence difference among the alleles, enzyme digestion will yield DNA
fragments with unique patterns of length, which can be distinguished by electrophoresis.
Compared to serotyping, PCR-RFLP method is specific, simple and rapid and does not re‐
quire probes. It can accurately detect single nucleotide difference and two linked polymor‐
phic sites. The disadvantage of this method is that if the enzyme cannot completely digest
the PCR product, the DNA fragments with similar lengths may be difficult to distinguish
after electrophoresis. In addition, alleles need to have endonuclease recognition sites. Fur‐
thermore, PCR-RFLP cannot distinguish certain HLA heterozygosities. It requires multiple
endonucleases for those alleles with high polymorphism such as HLA-DRB1, and may pro‐
duce complicated restriction maps. For these reasons, this method is rarely used for HLA
typing currently.
3.3. PCR-SSCP (single-strand conformation polymorphism)
Suzuki et al in Japan have found that a single-stranded DNA fragment has complex spatial
conformation. The three-dimensional structure is generated by the intramolecular interac‐
tions among the base pairs. The changing of one nucleotide may affect the spatial conforma‐
tion of the DNA strand. Single stranded DNA molecules have their unique size exclusion
characters in polyacrylamide gels due to their molecular weights and three-dimensional
structures. Therefore, they can be separated by non-denature polyacrylamide gel electro‐
phoresis (PAGE). This method is sensitive enough to distinguish molecules with subtle
structural differences, and it is called single-stranded conformation polymorphism (SSCP).
The authors later applied SSCP in the detection of mutations in PCR products and devel‐
oped PCR-SSCP technique, which has further improved the sensitivity and simplicity for
mutation detection.
This method is simple, rapid, sensitive, requiring no special equipment, and is suitable for clin‐
ical applications. However, this method can only detect mutations. The location and the type of
the mutation need to be determined by sequencing. In addition, the conditions of electrophore‐
sis need to be tightly controlled. Furthermore, point mutations in certain locations may have no
to little effect on the DNA conformation. Therefore, different DNA molecules may not be able
to separate by PAGE due to these reasons and other factors. Nevertheless, this method has a rel‐
atively high detection sensitivity compared with other methods. It can detect mutations in un‐
known locations in the DNA molecule. Takao has demonstrated that SSCP can detect 90% of
single nucleotide mutations in a DNA fragment smaller than 300bp. He believes that most
known single nucleotide mutations can be detected by this method. Mutant DNA molecules
can be separated and purified by PAGE due to the different migration rates, and the mutation
can be eventually identified by DNA sequencing.
In SSCP analysis, the separation of single stranded DNA by non denature PAGE is not just
based on their molecular weights and electric charges, but also on the retention force caused
by their spatial conformations. Therefore, the migration rate of a DNA fragment does not
The Advanced HLA Typing Strategies for Hematopoietic Stem Cell Transplantation
http://dx.doi.org/10.5772/53084
55
reflect its molecular size. Since the wild type and mutant DNA molecules may migrate very
closely and are difficult to distinguish, it is generally required for DNA molecules to migrate
for more than 16-18 cm in the gel. Mobility is calibrated using reference DNA as an internal
control. Because of these reasons, this method cannot clearly determine the HLA genotype.
3.4. PCR-SSO (sequence specific oligonucleotide)
In PCR-SSO, specific probes are synthesized according to the sequence in the HLA polymor‐
phic region. The target DNA fragment is amplified in vitro first. Then a specific probe will be
hybridized to the PCR product under certain conditions based on base pair complements.
The hybridized product can be detected by radioactive or non-radioactive signals. There are
two types of SSOP method, direct hybridization and reverse hybridization. In the direct hy‐
bridization, the PCR product is fixed on the membrane while in the reverse hybridization,
the probe is fixed on membrane. Figure 6 is the diagram of PCR-SSO.
Figure 6. The diagram of PCR-SSO process
In 1986, Saiki et al were the first to report the analysis of DQA1 polymorphism using PCR
and 4 allelic specific oligonucleotide (ASO) probes. MicKelson has typed the DR loci by se‐
rotyping and PCR-SSOP in 268 specimens. The success rate of serotyping is 91.0% while the
success rate of PCR-SSOP is 97.0%. Overall, PCR-SSOP has a high success rate, a wide
source of reagents, a high specificity and resolution. It can detect the difference of one nu‐
cleotide. In addition, PCR-SSOP can be used for a large number of samples with accurate
and reliable results. However, this method is time consuming. It often takes a few days and
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needs a large amount of probes. In addition, it is difficult to detect heterozygous alleles, par‐
ticularly those of the complicated HLA-DRB1 genes.
Overall, PCR-SSO is an accurate HLA genotyping method, and can identify all known HLA
alleles for accurate analysis of HLA polymorphism. HLA is a super gene family and new
alleles are continuously been identified. SSO probes can only be designed based on the se‐
quences of known alleles. Although PCR-SSO may discover new HLA polymorphism
through its hybridization pattern, dot-hybridization often leads to false positives. In addi‐
tion, when an allele is identified in the sample, it is difficult to determine whether the allele
is homozygous or heterozygous. Therefore, the HLA allele frequency and haplotype fre‐
quency cannot be precisely determined by this method.
3.5. PCR-SNP (single nucleotide polymorphism)
Single nucleotide polymorphism (SNP) is the inheritable and stable biallelic single nucleotide
difference. In the human genome, every 1000 base pairs have one to 10 SNPs. SNP may have
some regulatory functions in gene expression and protein activity. High SNP density has been
found in HLA class I genes with one SNP in every 400bp, setting the basis for high-throughput
MHC-SNP analysis. Compared with other methods, SNP is less time consuming and with a
low cost. Gou et al have developed a simple and effective oligonucleotide microarray to detect
SNPs in the coding sequence of HLA-B locus. Based on the known polymorphism in the exon 2
and 3 of HLA-B genes, 137 specific probes were designed. In a double-blind experiment, these
probes were used in the PCR-SNP analysis of 100 specimens from unrelated individuals. The
result showed that this method could explicitly identify all SNPs in the HLA-B locus. Bu Ying et
al have established a rapid, efficient, and cost effective SNP detection method using a single
tube. In this method, 4 primers are used for the PCR amplification. Two primers are used to am‐
plify the DNA fragment containing the SNP region, and the other two primers are SNP specific.
The primer extension error is significantly reduced when 4 primers simultaneously carry out
the PCR reaction, thereby the accuracy of SNP analysis is greatly improved. With the develop‐
ment of third-generation genetic markers, it is expected to find a series of single nucleotide
polymorphisms in the HLA complex, and generate high-density SNP maps. In order to devel‐
op SNP technology into a simple and effective HLA typing method, production of high-density
SNP maps in the HLA regions and development of HLA-SNP genotyping kits have been pro‐
posed in the 13th IHWC conference.
4. Reference-strand-mediated conformation analysis (RSCA)
Arguello et al devised the double-stranded conformation analysis (DSCA) technique in 1998
for the detection and analysis of gene mutations and complex polymorphic loci. Based on
this technique, reference strand mediated conformation analysis (RSCA) has been devel‐
oped. This is a major technical breakthrough in HLA typing. This technique combines se‐
quencing and conformational analysis to overcome the limitations of the methods that just
employ DNA sequencing or conformational analysis. The concept behind RSCA is that a flu‐
orescent labeled reference strand is hybridized with the amplified product of a specific gene
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to form stable double stranded DNA with unique conformation. After non-denature polya‐
crylamide gel electrophoresis or capillary electrophoresis, HLA alleles can be detected by la‐
ser scanning and computer software based analysis. Figure 7 is the basic procedure of
RSCA.
Figure 7. The basic procedure of RSCA
Compared with PCR-SSP, the most commonly used method of HLA genotyping, RSCA has
the following advantages: (1) high resolution and sensitivity. RSCA is based on the differen‐
tial migration rate of fluorescent-labeled double stranded DNA during the electrophoresis.
Innovations in Stem Cell Transplantation58
Alleles with different sequences will produce DNA duplexes with different spatial struc‐
tures after hybridization with their fluorescent labeled probes. Two alleles with one nucleo‐
tide difference will cause a change in the spatial structure of a hybridized duplex, resulting
in an altered migration rate in electrophoresis. Therefore, RSCA can distinguish the alleles
with a single nucleotide difference. For example, HLA-A*0207 and A*0209 alleles only differ
from one nucleotide at the site 368 of exon 3. In this site, A*0207 has a G while A*0207 has an
A. Likewise, HLA-A*0224 and A*0226 only differ from one nucleotide. These alleles all can
be distinguished by RSCA. (2) high reproducibility. In RSCA, each lane in the non-denature
polyacrylamide gel has markers and each gel has a DNA ladder. Therefore, the alteration
caused by different gels or lanes can be eliminated. (3) new allele or mutation identification.
RSCA is based on the electrophoretic mobility difference caused by different spatial struc‐
ture of the duplexes after allele-FLR hybridization. New alleles or mutations will have elec‐
trophoretic mobility different from that of known alleles. (4) RSCA can be applied at a large
scale with a low cost.
The disadvantages of RSCA are (1) time-consuming for a single sample; (2) requiring high
quality samples; PCR-SSP requires 10-100ng/ml of DNA, which can be obtained with a regu‐
lar DNA purification kit from patients even with a low amount of white blood cells. Howev‐
er, RSCA requires 50-100ng/ml of DNA. It may require an increased amount of blood
sample for patients with low levels of white blood cell in order to obtain sufficient DNA;
and (3) insufficient database.
5. Pyrosequencing: A high-resolution method for HLA typing
Pyrosequencing is a new HLA genotyping technology based on real time sequencing during
DNA amplification. The reaction system contains 4 enzymes (DNA polymerase, ATP sulfur‐
ylase, luciferase and apyrase), a substrate (APS: adenosine 5’ phosphosulfate), fluorescein
(luciferin), primers and the single stranded DNA template. After one type of dNTP (dATP,
dTTP, dCTP and dGTP) is added to the reaction system, it will be incorporated into the
newly synthesized chain if it is complementary to the nucleotide on the template. Incorpora‐
tion of dNTP will generate the same molar amount of pyrophosphate (PPi). ATP sulfurylase
converts APS and PPi into ATP, which provides energy for luciferase to oxidate luciferin
and emit light. The amount of light signal is proportional to the amount of ATP. The optical
signal is detected by a CCD (charge couple device) camera and generates a peak in the pyro‐
gram. The principle of Pyrosequencing is shown in Fig 8.
The height of each signal’s peak is proportional to the number of nucleotides incorperated.
Unincorporated dNTPs and excessive ATP are converted to dNDPs, which are further con‐
verted to dNMPs by apyrase. The optical signal is quenched and the system is regenerated
for the next reaction. The next dNTP can be added to the system to start the next reaction
after the unincorporated dNTPs and excessive ATP are removed. The reaction cycle contin‐
ues until the complementary DNA strand is synthesized. Under the room temperature, it
takes 3-4 seconds from polymerization to light detection. In this system, 1 pmol of DNA will
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generate 6x1011 pmol of ATP, which in turn yields 6x109 pmol of photon with a wavelength
of 560nm. The signal can be easily detected by a CCD camera. For the analysis of DNA with
an unknown sequence by Pyrosequencing, a cyclic nucleotide dispensation order (NDO) is
used. dATP, dGTP, dTTP and dCTP are sequentially added to the reaction. After one nu‐
cleotide is incorporated, the other three will be degraded by the apyrase. For the DNA with
a known sequence, non-cyclic NDO can be used and will yield a predicted pyrogram. The
sequence of the complementary DNA strand can be determined based on the NOD and
peak value in the pyrogram.
Figure 8. The principle of Pyrosequencing
Since nucleotides are differentially incorporated, Pyrosequencing can produce high-resolu‐
tion results. Typing HLA-DRB1*04, 07 and DRB4* in the donor’s DRB genes by Pyrose‐
quencing not only yields the same result as using the SSOP typing kit, but also produces the
result with a higher resolution. Compared with SSP, SSOP, direct or reverse hybridization,
Pyrosequencing can be used to solve ambiguous allele combinations of HLA-DQ and HLA-
A/B in a short time. The types of HLA-DQB1 and HLA-DRB alleles have been accurately de‐
termined by Pyrosequencing.
An inherent problem with this technology is the de novo sequencing of polymorphic region in
heterozygous DNA, although polymorphism can be detected in most cases. When the nucleo‐
tide in the polymorphic region is altered, synchronized extension can be achieved by the addi‐
tion of the substituted nucleotides. If there is a deletion or insertion in the polymorphic region,
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and the deleted or inserted nucleotide is the same as the adjacent nucleotide on the template,
the sequence after the polymorphic region will be synchronized. However, if the deleted or in‐
serted nucleotide is different from the adjacent nucleotide on the template, the sequence reac‐
tion can be out of phase, making the subsequent sequence analysis difficult. Another issue with
this technology is the difficulty in determining the number of incorporated nucleotides at the
homopolymeric region. The light signal will become nonlinear after the incorporation of more
than 5-6 nucleotides. Studies on the polymerization efficiency of the homopolymeric region
have shown that it is possible to incorporate less than 10 identical nucleotides in the presence of
apyrase. However, it needs a specific software algorithm of signal integration to determine the
precise number of incorporated nucleotides. For re-sequencing, the nucleotide is added twice
to ensure complete polymerization in the homopolymeric region. Another limitation of this
technology is the length of the sequencing.
6. Application of flow cytometry in HLA typing
Flow cytometry has failed to become a main method for HLA typing since it was applied to
the field of immunology for the first time in 1977. This is mainly due to the large number of
specific probes required for HLA typing. The flow analyzer LABScan100 that combines the
flow cytometry and reverse SSO technology is trending to replace three conventional meth‐
ods, SSO, SSP and SBT (sequence-based typing, direct sequencing), in HLA typing.
On a suspension platform, multiple types of color-coded beads conjugated with SSO probes
specifically bind to the single stranded DNA. Each type of bead has its unique spectral char‐
acteristics due to the different amount of fluorescent dye conjugated to the beads. When
beads pass through a flow cytometer, the difference in the light scattering pattern from vari‐
ous angles can distinguish HLA genotypes.
Currently, LabType TM SSO is a relatively more mature technique compared with others in
HLA typing. Its unique advantage is that thousands of molecules can be simultaneously an‐
alyzed in a matter of seconds. Therefore, this technique can be used for a large-scale analy‐
sis. Overall, this technique has the following advantages: (1) It has increased accuracy due to
the automated detection system. (2) The workload and reagent consumption are reduced.
One reaction tube can have 100 different SSO probes, thus greatly reducing the workload
and reagent consumption. (3) It produces rapid and objective results. The ambiguous results
can be avoided with Specialty Probe Technology TM (SP Technology). (4) Unlike regular flow
cytometry that requires fresh samples, this technique can examine the sample at any time
upon request or retrospectively. DNA samples can be analyzed right after extraction or stor‐
ed at –20oC for more than 1 year without affecting the results. (5) The technique can analyze
multiple HLA loci with low, medium and high resolutions. (6) It can be used in laboratories
with large or small samples. More than 100 probes can be put in one test tube for one sample
or in a 96-well plate for 96 samples. The analysis of 96 samples takes less than 90 min after
amplification. (7) The pollution to the environment and potential harm to the staff are re‐
duced because electrophoresis is not required in this method.
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7. Gene chip or DNA microarray
In gene chip or DNA microarray, large amount of probe molecules (usually 6x104
molecules/cm2) are attached to a solid surface. Labeled DNA samples are hybridized to the
probes. The amount and sequence information of the target can be determined by the inten‐
sity of the hybridization signal. Gene chip or DNA microarray technology was first devel‐
oped by Affymetrix in the USA, and has been improved significantly within a few years.
The technology is based on the principle of reverse dot hybridization. Thousands of oligo‐
nucleotide probes representing different genes are spotted on a solid surface by a robot.
These probes will bind to radioactive isotope or fluorescent dye labeled DNA or cDNA
through complementary sequences. After autoradiography or fluorescence detection, signals
are processed and analyzed by computer software. The intensity and distribution of hybridi‐
zation signal reflect the expression level of the gene in the sample. The operation process of
microarray is shown in Fig 9. Balazs et al spotted amplified DNA samples on silicon chips
and compared the microarray results with PCR-SSO results in 768 specimens. It has been
found that microarray has a high sensitivity and specificity. The consistent rate of genotyp‐
ing results from microarray and PCR-SSO is 99.9%.
Figure 9. The procedure of gene chip/microarray analysis
Compared with existing genotyping methods, gene chip or microarray has the following ad‐
vantages: (1) High intensity. The dot intensity on a chip can be higher than 6x104/cm2. There‐
fore, probes to thousands of HLA-A, B, C, DR, DQ and DP sequences can be spotted on a
tiny chip of several square centimeters to obtain the information of individual HLA genes
simultaneously. (2) High resolution. It can obtain information at the allele level. (3) Simple
operation. The results are generated by fluorescence scanning instead of gel electrophoresis,
which greatly simplifies the procedure and shortens operation time. (4) High sensitivity.
Signals are amplified twice, first, PCR amplification of the template DNA and second, am‐
plification of fluorescence signal. Therefore, the sensitivity is greatly improved. (5)High ac‐
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curacy. The intensity of the fluorescent signal generated by the perfect pairing of the probe
and the sample is 5 to 35 times higher than the signal generated by the probe and the sample
with one or two mismatched nucleotides. Accurate detection of fluorescent signal intensity
is the basis of the detection specificity. Studies have shown that the consistency between mi‐
croarray and Sanger sequencing in the detection of mutations and polymorphism is 99.9%.
(6) High efficiency. The whole process is highly automatic, which saves manpower and time
for data analysis. Genotyping of genes such as HLA-A, B, DR and DQ in multiple samples
can be done with one PCR reaction and hybridization on one chip. (7) High level of stand‐
ardization. Using a variety of multi-point synchronized hybridization and automated analy‐
sis, the human error is minimized to ensure the specificity and objectivity. (8) Low cost.
Since the chip fabrication and signal detection are all automatic, only a small amount of
probes and samples are required. One chip can be used for the analysis of samples from
multiple individuals, which further reduces the cost. The biggest drawback of microarray
analysis is its expensive equipment, which prevents it from becoming widely used. Only in‐
stitutions with a large program can afford the equipment.
8. DNA sequencing technology
For the analysis of gene structure, sequencing is the most direct and accurate method. In this
case, the DNA fragment is amplified by PCR and followed by sequencing. The basic process
of this method is shown in Figure 10. Since the entire nucleotide sequence of the amplified
fragment is obtained, this is the most reliable and thorough genotyping method. It can not
only identify the sequence and genotype, but also lead to the discovery of new genotypes.
Currently, the newly identified HLA alleles can only be verified by sequencing. It has been
reported that if the HLA type cannot be determined by serotyping or the results from PCR-
SSP and PCR-SSOP are inconsistent, sequence-based typing (SBT) often can yield accurate
and reliable results with a high resolution. Hurley et al have typed HLA alleles by PCR-STB
in 1775 bone marrow transplant patients and unrelated donors in NMDP, USA. The study
has found that the degree of HLA allele mismatching between the recipient and donor of
bone marrow transplantation is much higher than previously thought after examining the
antigen matching results of HLA-A, HLA-B and HLA-DR.
The advantage of SBT over PCR-SSP and PCR-SSOP is its ability to analyze the entire gene
sequence including the non-polymorphic region. SBT can be used not only for DNA se‐
quencing but also for cDNA sequencing to determine gene expression. With increasing pop‐
ularity of DNA sequencing technology, the PCR-SBT method has gained much attention for
genotyping. PCR-SBT has advantages over other typing methods in terms of accuracy, effi‐
ciency and the degree of automation. Specialized software and solid phase sequencing kits
with automatic loading are available for HLA typing. In addition, the cost of DNA sequenc‐
ing has been greatly reduced. Therefore, PCR-SBT is an ideal method for HLA typing in re‐
searches. With further decrease in the cost of automatic sequencing, this genotyping method
will be widely used.
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Currently, PCR-SBT is the gold standard of HLA typing. This method has several advantag‐
es: (1) It can accurately determine gene type in the exon 8 by a high-resolution sequencing,
sufficient to meet the need in researches and clinics. (2) It can analyze more than 15,000 sam‐
ples every month with high throughput detection. (3) Automated SOP and advanced data
management system can reduce human error. (4) It has high quality assurance. Ten percent
blind samples are used repeatedly as internal quality control and 100% accuracy is achieved
for 10 consecutive times using UCLA external quality assurance samples. The results are
confirmed by SSP. (5). It may lead to the discovery of new alleles. (6) HLA genotype can be
updated by re-analyzing the sequence after the HLA database is updated.









Figure 10. The diagram of DNA sequencing
9. Conclusion
Hematopoietic stem cell transplantation has become one of the most effective treatments for
a variety of hematologic malignancies. However, graft-versus-host disease (GVHD) is still
inevitable in some cases. This is mainly due to the difference in the major histocompatibility
complex (human leukocyte antigen, HLA) between the recipient and the donor. Other
known and unknown factors that may cause GVHD include minor histocompatibility anti‐
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gen (mHA) and tissue specific antigens. GVHD is the main cause of transplant failure in the
allogeneic transplantation. Therefore, GVHD is the most significant challenge in allogeneic
hematopoietic stem cell transplantation in clinics. It has been proven that whether the graft
can survive largely depends on the degree of HLA matching between the recipient and the
donor. Therefore, HLA typing of the recipient and the donor before the transplantation is
particularly important.
Currently, PCR-SSP genotyping is a commonly used method for HLA typing in clinical lab‐
oratories worldwide. Like SSP method, PCR-SSP method depends on specific primers for
genotyping. Although the process is simple and rapid, high-resolution genotyping requires
a large number of sequence specific primers, which leads to a high cost and prolonged oper‐
ation time. Similarly, SSO technique is based on the sequence-specific oligonucleotide
probes. High-resolution genotyping by SSO significantly increases the cost and complexity.
Therefore, it is rarely used for HLA typing today. PCR-SNP is a simple and fast method
with a high resolution, and PCR-SNP is expected to become more popular in HLA typing as
the technology continues to improve. Although RSCA and Pyrosequencing can achieve
high-resolution results, their applications in HLA typing will be gradually eliminated as the
technology of gene chip and sequencing continues to improve and the cost continues to de‐
crease. HLA-chip genotyping is still largely dependent on the known sequence. It cannot
identify new alleles with unknown sequence. At this moment, PCR-SBT technology has sig‐
nificant advantages over other HLA typing methods in terms of accuracy, efficiency and au‐
tomation. There are specialized software and automatically loaded sequencing reagents for
HLA typing by PCR-SBT. In addition, the operation cost has been greatly reduced. In con‐
clusion, PCR-SBT technology with HLA-chip is the best method for HLA typing in research.
With the reduction in the cost of automated nucleic acid sequencing, this genotyping meth‐
od will be widely used in the field of basic research as well as in clinical transplantation.
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